Melvin Chan
LightNews LightNews
mchanmd.bsky.social
Melvin Chan
@mchanmd.bsky.social
650 followers 850 following 89 posts
Current NSMC Faculty, CU Ped Neph, and IM faculty; interested in CKM and transition of care
Posts Replies Media Videos
Pinned
mchanmd.bsky.social
Melvin Chan @mchanmd.bsky.social · Nov 13
📌
mchanmd.bsky.social
More tools for our advanced CKD patients!
kireports.bsky.social kireports.bsky.social @kireports.bsky.social · 5d
🧵 New #Skeetorial Drop! 🧵
1/ Hey #NephSky! 👋
We’re back with a fresh #Skeetorial from @kireports.bsky.social , this time diving into:
Dapagliflozin in Stage 4 CKD: no diabetes required? 🤔
Let’s unpack what this trial means for your next CKD patient. 💊💭
November 20, 2025 at 6:59 PM
Reposted by Melvin Chan
rheaultm.bsky.social
Late breakers that included children:
✅Setanaxib in Alport (12+)

Late breakers that did NOT include children:
🚫Atacicept in IgAN
🚫CONFIDENCE
🚫PISCES: Fish oil in Dialysis
🚫LIBERATE-D
🚫balcinrenone + dapa
🚫Obintuzumab in lupus nephritis
🚫Sibeprenlimab in IgA
🚫MIL62 in membranous
+more
#KidneyWk
November 8, 2025 at 8:27 PM
Reposted by Melvin Chan
nephjc.bsky.social
🎨Beautiful visual abstract by Dr Natalia Nombera @roxnonna23.bsky.social #NephJC

www.nephjc.com/news/...
October 29, 2025 at 1:04 AM
mchanmd.bsky.social
Great read on ways of measuring renal function. Shout out to @elbaonelida.bsky.social

www.kireportscommunity.org/post/towards...
Towards new ways of assessing kidney function. Where to look to improve?
Written by Elba MedinaReviewed by Brian Rifkin;Sophia AmbrusoToday, current methods for measuring kidney function, due to several critical limitations, need to be reimagined. In the reimagining Kidney...
www.kireportscommunity.org
October 26, 2025 at 2:46 AM
mchanmd.bsky.social
A great read on the history and upcoming anticoagulation targets especially for our dialysis patients! #NephSky

www.kireportscommunity.org/post/bleedin...
Bleeding, Clotting, and Kidney Disease in Atrial Fibrillation: Can Factor XI Inhibitors Change the Game?
Explore how we are uncoupling hemostasis and thrombosis via Factor XI inhibitors and how it is may change anticoagulation for atrial fibrillation in kidney disease
www.kireportscommunity.org
October 2, 2025 at 7:44 PM
mchanmd.bsky.social
Looks like tirzepatide have benefits for those with T1DM, with insulin needs reduced within 2 weeks of treatment. #NephSky #MedSky

www.medscape.com/viewarticle/...
First Randomized Trial of Tirzepatide in T1D Shows Benefits
Tirzepatide reduced weight, A1c, and insulin dose in type 1 diabetes in a small randomized controlled trial.
www.medscape.com
September 27, 2025 at 11:13 PM
Reposted by Melvin Chan
nephjc.bsky.social
Change is in the Autumn air 🌬️🍂
Join use only on #Bluesky on 9/16/25 at 9pm EST.
We're discussing the 2025 ACC/AHA Hypertension Guideline Update. 🫀🫘🧠 #NephSky #MedSky
www.nephjc.com/news/accaha2025-klno3
PREVENT, Detect, Treat: What’s New in the 2025 Hypertension Toolkit — NephJC
This week, we will discuss the AHA/ACC 2025 hypertension guideline update. Wow, have eight years flown by?
www.nephjc.com
September 15, 2025 at 10:07 PM
mchanmd.bsky.social
There’s continued growing evidence that childhood onset hypertension leads to worse outcomes.
jama.com JAMA @jama.com · Sep 14
In a large sample of US children born between 1959 and 1966, higher #BloodPressure at age 7 years was associated with greater risk of premature #cardiovascular disease mortality.

ja.ma/4meFZCO
JAMA "High Blood Pressure in Childhood and Premature Cardiovascular Disease Mortality" research letter. Graphs show cumulative incidence of mortality vs. age, stratified by blood pressure. Hypertension, elevated BP, and normal BP are compared.
September 14, 2025 at 4:09 PM
mchanmd.bsky.social
Thoughts about Wegovy vs Zepbound for MACE Reduction? #MedSky #NephSky

Finding:
-Semaglutide showed 29% reduction in MACE

Limits:
-Small # of events
-Retrospective

Implications:
-Wegovy may be better for those with ASCVD
-Does GIP have any CV benefits?

sciencehub.novonordisk.com/content/dam/...
sciencehub.novonordisk.com
September 11, 2025 at 6:02 PM
Reposted by Melvin Chan
brianrifkin.bsky.social
Check out the latest @kireports.bsky.social community blog from @husamjz.bsky.social
Anticoagulantion in ESRD patients with atrial fibrillation:
www.kireportscommunity.org/post/bleeding-clotting-and-kidney-disease-in-atrial-fibrillation-can-factor-xi-inhibitors-change-the-g
Bleeding, Clotting, and Kidney Disease in Atrial Fibrillation: Can Factor XI Inhibitors Change the Game?
By. Husam Alzayer, MD, MSc, MRCPIReviewed by Sophia Ambruso, DOIntroduction Bleeding and thrombosis represent one of the many paradoxes faced by patients with kidney disease. As kidney function declin...
www.kireportscommunity.org
September 8, 2025 at 11:36 PM
Reposted by Melvin Chan
nephjc.bsky.social
🤔 How often is end-stage kidney disease in patients with MCD/ FSGS? #NephSky #MedSky

@brianrifkin.bsky.social dissected the conclusions from the RaDar study in this #NephJCshorts

*the original article from @asnpublications.bsky.social

www.nephjc.com/news/nephjc-...
NephJC Shorts: MCD and FSGS Outcomes — NephJC
A NephJC Shorts discussion of the long term data on kidney failure in FSGS and MCD
www.nephjc.com
September 6, 2025 at 5:00 PM
Reposted by Melvin Chan
nephjc.bsky.social
Check out the ACHIEVE visual abstract by @nephromommy-akshu.bsky.social

www.nephjc.com/news/2025/8/...
The ACHIEVE visual abstract — NephJC
the use of spironolactone in patients on dialysis did not alter mortality or hospitalizations for heart failure. Similar results were seen in the simultaneously released ALCHEMY trial.
www.nephjc.com
September 1, 2025 at 10:50 PM
Reposted by Melvin Chan
kireports.bsky.social
Please share this #Skytorial with your followers and friends!
Don't forget to check out KI Reports Community for more: kireportscommunity.org. Thanks to @sophia-kidney.bsky.social, @brianrifkin.bsky.social, and @mchanmd.bsky.social for great feedback!
August 16, 2025 at 6:18 AM
mchanmd.bsky.social
Bought a construction truck food mat for my 4.5 year old. Instead of letting the food particles stay there he pushes it to the floor to keep the mat clean. “ChildPerspectives
May 27, 2025 at 12:57 AM
mchanmd.bsky.social
For all my little beans out there, don’t forget to read the latest recommendations on IgAN and IgAVN by @mdabdulqader83.bsky.social on @kireports.bsky.social

www.kireportscommunity.org/post/navigat...
Navigating the Challenges of IgA Nephropathy and IgA Vasculitis Nephritis in Children
Written by: Henny Adriani PuspitasariIntroduction:IgA nephropathy (IgAN) and IgA vasculitis nephritis (IgAVN) are kidney diseases that can significantly impact children's health. While they share some...
www.kireportscommunity.org
May 6, 2025 at 2:05 AM
Reposted by Melvin Chan
kireports.bsky.social
💥Hey #NephSky! Welcome to a 🆕 #tweetorial #xtorial brought to you by @KIReports @ISNkidneycare #Skytorial. Our author is @elbaonelida.bsky.social nephrologist at Hospital General de Mexico @hgm_nefrologia. Please also check out www.kireportscommunity.org educational #blogposts. FOLLOW US!🫰
April 19, 2025 at 1:20 AM
Reposted by Melvin Chan
kireports.bsky.social
🚨Hey #NephSky!
Welcome to a new #Medsky #Skytorial brought to you by @kireports.bsky.social
Our author is @brianrifkin.bsky.social nephrologist in Hattiesburg, MS
Please check out #KIReportsCommunity educational #blogposts too!
March 26, 2025 at 5:42 PM
Reposted by Melvin Chan
nephjc.bsky.social
⏰2 hours to chat
It’s #NephJC time! Tonight we dive into something BIG —literally & figuratively: the first-ever @kdigo.org 2025 ADPKD guidelines 🧬
Finally, this disease gets its own spotlight. #NephJC
KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PubMed
KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
pubmed.ncbi.nlm.nih.gov
March 25, 2025 at 11:00 PM
mchanmd.bsky.social
What is the evidence of SGLT in cystic kidney disease? #askrenal @kireports.bsky.social
March 23, 2025 at 12:47 PM
Reposted by Melvin Chan
divyaveerssneph.bsky.social
🆕 🥇FDA approved therapy for C3 Glomerulopathy
Iptacopan : inhibitor of the alternative complement pathway by specifically binding to and inhibiting factor B
#Hope for #kidney #disease
#Great time to be in #Nephrology
#Nephsky #Nephbluesky #Medsky #Medbluesky #Nephronuggets
March 21, 2025 at 12:04 PM
mchanmd.bsky.social
It is March. Do you know what that means? #NephMadness @nephmadness.bsky.social ! Today let's chat about obesity in transplant donors and recipients! Here is a link to the blog:
ajkdblog.org/2025/03/01/n...
#NephMadness 2025: Obesity in Kidney Transplant Region
Submit your picks! | @NephMadness | @nephmadness.bsky.social | NephMadness 2025 Selection Committee Member: Swee-Ling Levea @SweeLevea Swee-Ling Levea is an Associate Professor of Medicine at Unive…
ajkdblog.org
March 2, 2025 at 11:58 PM
Reposted by Melvin Chan
drpallaviprasad.bsky.social
COI; I have never EVER done these tests .anyone using these in their practice? #NephJC @kidneyboy.bsky.social ?
February 12, 2025 at 2:23 AM
Reposted by Melvin Chan
nephjc.bsky.social
Think primary aldosteronism means hypertension, hypokalemia and metabolic alkalosis...think again. Can undercover hyperaldosteronism be a key to CKD?🔎
#NephJC chat 2/11/25 at 9pm EST #NephSky
www.nephjc.com/news/primary...
Undercover Aldosterone — NephJC
This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?
www.nephjc.com
February 10, 2025 at 9:26 PM
Reposted by Melvin Chan
brianrifkin.bsky.social
But what if…primary hyperaldosteronism is more common then we thought, even in normotensive people without CKD, and the root cause of a significant number of “hypertensive nephrosclerosis” patients?
(Sneak peak at our next #NephJC for 2/11/25)
February 3, 2025 at 11:58 PM
mchanmd.bsky.social
Great work! 👏
February 2, 2025 at 11:02 PM